
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics NV is positioned for potential stock price appreciation due to the prospects of successfully advancing its pipeline products and achieving proof of concept data in human trials. The company’s promising Axiomer RNA base-editing platform is anticipated to provide clinical data that could significantly enhance its valuation. Additionally, with a robust cash position that supports operations into mid-2027, ProQR is strategically equipped to navigate its clinical development timeline.
Bears say
ProQR Therapeutics NV reported a net loss of €12.2 million for the quarter, a substantial increase compared to the €2.7 million loss in the same period in 2024, reflecting escalating financial challenges. The company's reliance on the outcomes of future Phase Ib/II/III studies presents significant uncertainty, as negative results could severely impact investor confidence and stock performance. Additionally, advancements in treatment methods for the diseases ProQR targets could potentially render the company's RNA-based therapies obsolete, further jeopardizing its market position and long-term viability.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares